Biogen Hemophilia A Product May Win Patients Who Shun Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec released top-line data from a pivotal trial testing its long-acting Factor VIII therapy in three arms, one of which offered an extended dosing option that could appeal to the 65% of hemophilia A patients who seek treatment only when they experience a bleed.